Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Rhea-AI Summary

Coherus Oncology (NASDAQ: CHRS) will present a poster at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), Nov 5-9, 2025, in National Harbor, Maryland. Abstract #640 reports that CHS-114, an anti-CCR8 cytolytic monoclonal antibody, “demonstrates selective intratumoral Treg depletion and favorable immune remodeling” in participants with advanced solid tumors. The poster presentation is scheduled for Saturday, November 8, 2025 at Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.

Additionally, CHS-114 will be featured in SITC’s webinar series "Targets for Cancer IO: A Deep Dive" on October 22, 2025, 12:00–2:00 PM ET, covering CCR8 biology and clinical results, with Coherus faculty Rosh Dias, MD and Varun Kapoor, PhD.

– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –

REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland.

Abstract # 640: CHS-114, an anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors.

• Date: Saturday, November 8, 2025
• Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center

In addition, CHS-114 will be featured in the upcoming Targets for Cancer IO: A Deep Dive live webinar series:
Development of Anti-CCR8 Ab - Mechanisms and Clinical Results
Webinar 6 will address the novel therapeutic target C-C chemokine receptor 8 (CCR8), its role in regulatory T cell (Treg) activity and immunosuppression, and the latest advances and insights in developing monoclonal antibodies that target this chemokine receptor as a promising new strategy to treat a variety of cancers.

• Date and Time: October 22, 2025, 12:00 – 2:00 pm Eastern Time
• Moderators: Enrico Lugli, PhD, Humanitas Research Hospital and Rahul Roychoudhuri, MD, PhD
  University of Cambridge
• Faculty: Rosh Dias, MD, MRCP, Coherus Oncology; Varun Kapoor, PhD, Coherus Oncology; Jo Van Ginderachter, PhD, Vrije Universiteit Brussel
  

To learn more about the webinar series and register to attend, visit SITC’s Targets for Cancer IO: A Deep Dive website: https://www.sitcancer.org/edu/webinars/targets-for-cancer-io

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), growing revenues and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its partners, driving sales multiples and synergies from proprietary combinations.

Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors, including non-small cell lung cancer and HCC. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck cancer, colorectal cancer, gastric cancer, and esophageal cancer.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.

Forward-Looking Statements

The statements in this press release include express or implied forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act about Coherus that involve risks and uncertainties relating to future events and the future performance of Coherus. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity,” “likely,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the ability of Coherus’ pipeline to enhance outcomes for cancer patients; expectations about future synergies; projections about growth in sales or revenues; expectations about advancing product candidates through clinical trials; and the assumptions underlying or relating to such statements.

These forward-looking statements are based on Coherus’ current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, assumptions and changes in circumstances, many of which are beyond the control of Coherus. A number of important factors, including those described in this press release, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties about the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, economic performance, indebtedness, financial condition and losses on Coherus’ prospects, business and operations in the future; risks and uncertainties of conducting clinical trials; the risks of Coherus’ dependence on an ability to raise funds, which may not be available on acceptable terms or at all; and risks and uncertainties of any litigation, regulatory actions and other legal proceedings.

While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the transaction described above will in fact be consummated in the manner described or at all. For a further discussion of these and other factors that could cause Coherus’ future results to differ materially from any forward-looking statements see the section entitled “Risk Factors” in Coherus’ Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission (SEC) on August 7, 2025, as updated by Coherus’ subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are made based on the current good faith beliefs and judgments of Coherus’ management, and the reader is cautioned not to rely on any forward-looking statements made by Coherus. Unless required by law, Coherus is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.

LOQTORZI^® is a registered trademark of Coherus Oncology, Inc.
©2025 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com

FAQ

When will Coherus Oncology (CHRS) present the CHS-114 poster at SITC 2025?

The CHS-114 poster (Abstract #640) is scheduled for Saturday, November 8, 2025 at SITC in National Harbor, Maryland.

What does Coherus' SITC abstract #640 say about CHS-114 (CHRS)?

Abstract #640 reports CHS-114 demonstrates selective intratumoral Treg depletion and favorable immune remodeling in advanced solid tumor participants.

Where and when is the SITC 40th Annual Meeting taking place for CHRS attendees?

SITC 2025 will be held Nov 5–9, 2025 at Gaylord National Resort and Convention Center, National Harbor, Maryland.

When is the CHS-114 webinar in SITC’s "Targets for Cancer IO: A Deep Dive" series?

CHS-114 will be featured in Webinar 6 on October 22, 2025, 12:00–2:00 PM ET.

Who from Coherus will present CHS-114 in the SITC webinar on Oct 22, 2025?

Coherus faculty listed are Rosh Dias, MD, MRCP and Varun Kapoor, PhD.

How can investors register to view the SITC CHS-114 webinar or find the poster details?

Register and find details at SITC’s "Targets for Cancer IO: A Deep Dive" webpage: https://www.sitcancer.org/edu/webinars/targets-for-cancer-io.